Distribution of treatment outcome among childhood extensively drug-resistant tuberculosis patients (N=42)
| Characteristics | Treatment outcome | p-value | |
| Successful | Unsuccessful | ||
| Age | 0.537 | ||
| <10 years | 9 (45%) | 11 (55%) | |
| 10–14 years | 12 (54.5%) | 10 (45.5%) | |
| Baseline weight | 0.525 | ||
| ≤35 kg | 7 (43.8%) | 9 (56.2%) | |
| >35 kg | 14 (53.8%) | 12 (46.2%) | |
| Sex | 0.495 | ||
| Female | 14 (46.7%) | 16 (53.3%) | |
| Male | 7 (58.3%) | 5 (41.7%) | |
| History of TB treatment | 0.726 | ||
| No | 5 (45.5%) | 6 (54.5%) | |
| Yes | 16 (51.6%) | 15 (48.4%) | |
| History of use of SLD | 0.095 | ||
| No | 17 (58.6%) | 12 (41.4%) | |
| Yes | 4 (30.8%) | 9 (69.2%) | |
| History of MDR-TB treatment | 0.079 | ||
| No | 18 (58.1%) | 13 (41.9%) | |
| Yes | 3 (27.3%) | 8 (72.7%) | |
| Comorbidities | 1.000 | ||
| No | 21 (52.5%) | 19 (47.5%) | |
| Yes | 0 (0.0%) | 2 (100%) | |
| Baseline sputum smear grading | Not measured | ||
| Negative | 3 (37.5%) | 5 (62.5%) | |
| Scanty# | 1 (100%) | 0 (0.0%) | |
| +1¶ | 11 (64.7%) | 6 (35.3%) | |
| +2+ | 1 (16.7%) | 5 (83.3%) | |
| +3§ | 5 (50%) | 5 (50%) | |
| Sputum culture conversion | 0.976 | ||
| <2 months | 13 (72.2%) | 5 (27.8%) | |
| >2 months | 8 (72.7%) | 3 (27.3%) | |
| Use of linezolid | 0.726 | ||
| No | 5 (45.5%) | 6 (54.6%) | |
| Yes | 16 (51.6%) | 15 (48.4%) | |
| Use of clofazimine | 0.064 | ||
| No | 14 (63.6%) | 8 (36.4%) | |
| Yes | 7 (35%) | 13 (65%) | |
| Use of bedaquiline | 0.634 | ||
| No | 18 (48.6%) | 19 (51.4%) | |
| Yes | 3 (60%) | 2 (40%) | |
TB: tuberculosis; SLD: second-line drug; MDR: multidrug-resistant. #: 1–9 acid-fast bacilli (AFB) per 100 high-power fields (HPFs); ¶: 10–99 AFB per 100 HPFs; +: 1–9 AFB per HPF; §: >9 AFB per HPF.